These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33740205)

  • 21. Neoadjuvant therapy in the treatment of breast cancer.
    Teshome M; Hunt KK
    Surg Oncol Clin N Am; 2014 Jul; 23(3):505-23. PubMed ID: 24882348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial.
    Fallowfield LJ; Hall A; Maguire GP; Baum M
    BMJ; 1990 Sep; 301(6752):575-80. PubMed ID: 2242455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A survey of Australian and New Zealand clinical practice with neoadjuvant systemic therapy for breast cancer.
    Zdenkowski N; Butow P; Mann GB; Fewster S; Beckmore C; Isaacs R; Douglas C; Boyle FM
    Intern Med J; 2016 Jun; 46(6):677-83. PubMed ID: 26929045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer.
    Bondiau PY; Courdi A; Bahadoran P; Chamorey E; Queille-Roussel C; Lallement M; Birtwisle-Peyrottes I; Chapellier C; Pacquelet-Cheli S; Ferrero JM
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1193-9. PubMed ID: 23332384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast conservation after neoadjuvant chemotherapy.
    Sadetzki S; Oberman B; Zipple D; Kaufman B; Rizel S; Novikov I; Papa MZ
    Ann Surg Oncol; 2005 Jun; 12(6):480-7. PubMed ID: 15868065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
    Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
    Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients.
    Franco P; Iorio GC; Bartoncini S; Airoldi M; De Sanctis C; Castellano I; Ricardi U
    Med Oncol; 2018 Apr; 35(5):62. PubMed ID: 29616366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moving Forward with Omission of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy.
    Kuerer HM
    Ann Surg Oncol; 2022 Dec; 29(13):7942-7944. PubMed ID: 36002702
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response.
    Mandish SF; Gaskins JT; Yusuf MB; Amer YM; Eldredge-Hindy H
    Acta Oncol; 2020 Oct; 59(10):1210-1217. PubMed ID: 32716227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China.
    Chen R; Li S; Li Y; Zhu Q; Shi X; Xu L; Xu Y; Zhang W; Huang X; Wang J; Zha X
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3495-3501. PubMed ID: 34398298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States.
    Mohiuddin JJ; Deal AM; Carey LA; Lund JL; Baker BR; Zagar TM; Jones EL; Marks LB; Chen RC
    J Am Coll Surg; 2016 Nov; 223(5):717-728.e4. PubMed ID: 27788894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant Chemotherapy for Breast Cancer, Is Practice Changing? A Population-Based Review of Current Surgical Trends.
    Graham PJ; Brar MS; Foster T; McCall M; Bouchard-Fortier A; Temple W; Quan ML
    Ann Surg Oncol; 2015 Oct; 22(10):3376-82. PubMed ID: 26202561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment recommendations for older women with breast cancer: A survey among surgical, radiation and medical oncologists.
    Hamelinck VC; Stiggelbout AM; van de Velde CJH; Liefers GJ; Bastiaannet E
    Eur J Surg Oncol; 2017 Jul; 43(7):1288-1296. PubMed ID: 28258786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic image-guided neoadjuvant ablative single-dose radiation, then lumpectomy, for early breast cancer: the SIGNAL prospective single-arm trial of single-dose radiation therapy.
    Guidolin K; Yaremko B; Lynn K; Gaede S; Kornecki A; Muscedere G; BenNachum I; Shmuilovich O; Mouawad M; Yu E; Sexton T; Gelman N; Moiseenko V; Brackstone M; Lock M
    Curr Oncol; 2019 Jun; 26(3):e334-e340. PubMed ID: 31285677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks.
    Buchholz TA; Hunt KK; Whitman GJ; Sahin AA; Hortobagyi GN
    Cancer; 2003 Sep; 98(6):1150-60. PubMed ID: 12973838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI in the evaluation of breast cancer patient response to neoadjuvant chemotherapy: predictive factors for breast conservative surgery.
    Nadrljanski MM; Miloševic ZC; Plešinac-Karapandžic V; Maksimovic R
    Diagn Interv Radiol; 2013; 19(6):463-70. PubMed ID: 24047722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
    Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
    Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer.
    Sharma P; Connolly RM; Roussos Torres ET; Thompson A
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-16. PubMed ID: 32315235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer.
    Morrow M; Jagsi R; McLeod MC; Shumway D; Katz SJ
    JAMA Oncol; 2018 Nov; 4(11):1511-1516. PubMed ID: 30003237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.